BR112021022089A2 - Materiais e métodos para modulação da imunidade mediada por células t - Google Patents

Materiais e métodos para modulação da imunidade mediada por células t

Info

Publication number
BR112021022089A2
BR112021022089A2 BR112021022089A BR112021022089A BR112021022089A2 BR 112021022089 A2 BR112021022089 A2 BR 112021022089A2 BR 112021022089 A BR112021022089 A BR 112021022089A BR 112021022089 A BR112021022089 A BR 112021022089A BR 112021022089 A2 BR112021022089 A2 BR 112021022089A2
Authority
BR
Brazil
Prior art keywords
methods
antibodies
modulating
cell
materials
Prior art date
Application number
BR112021022089A
Other languages
English (en)
Inventor
S Grewal Iqbal
Rajkumar Ganesan
Sanjaya Singh
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112021022089A2 publication Critical patent/BR112021022089A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

materiais e métodos para modulação da imunidade mediada por células t. são descritos anticorpos anti-trgv9 ou fragmento de ligação a antígeno dos mesmos. são descritos, também, ácidos nucleicos que codificam os anticorpos, composições que compreendem os anticorpos, métodos de produção dos anticorpos e métodos de uso dos anticorpos para tratamento ou prevenção de doenças, como câncer.
BR112021022089A 2019-05-08 2020-05-07 Materiais e métodos para modulação da imunidade mediada por células t BR112021022089A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962844976P 2019-05-08 2019-05-08
US201962844970P 2019-05-08 2019-05-08
US201962844959P 2019-05-08 2019-05-08
US201962844966P 2019-05-08 2019-05-08
US201962844995P 2019-05-08 2019-05-08
PCT/US2020/031749 WO2020227457A1 (en) 2019-05-08 2020-05-07 Materials and methods for modulating t cell mediated immunity

Publications (1)

Publication Number Publication Date
BR112021022089A2 true BR112021022089A2 (pt) 2022-02-08

Family

ID=73051172

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022089A BR112021022089A2 (pt) 2019-05-08 2020-05-07 Materiais e métodos para modulação da imunidade mediada por células t

Country Status (21)

Country Link
US (2) US11667712B2 (pt)
EP (1) EP3965818A4 (pt)
JP (1) JP2022533538A (pt)
KR (1) KR20220017892A (pt)
CN (1) CN113966231A (pt)
AU (1) AU2020267504A1 (pt)
BR (1) BR112021022089A2 (pt)
CA (1) CA3139508A1 (pt)
CL (1) CL2021002905A1 (pt)
CO (1) CO2021015998A2 (pt)
CR (1) CR20210548A (pt)
DO (1) DOP2021000229A (pt)
EC (1) ECSP21087921A (pt)
IL (1) IL287817A (pt)
JO (1) JOP20210297A1 (pt)
MA (1) MA55903A (pt)
MX (1) MX2021013532A (pt)
PE (1) PE20220763A1 (pt)
SG (1) SG11202112021QA (pt)
TW (1) TW202108618A (pt)
WO (1) WO2020227457A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210284731A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
KR20230169950A (ko) 2021-02-26 2023-12-18 라바 테라퓨틱스 엔.브이. Cd123 및 감마-델타 t 세포 수용체에 결합하는 항체

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2005538682A (ja) 2001-12-03 2005-12-22 アブジェニックス・インコーポレーテッド カルボキシックアンヒドラーゼｉｘ（ｃａｉｘ）腫瘍抗原に対する抗体
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
DK3050963T3 (da) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
EP2626371A1 (en) 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP2347038A4 (en) 2008-10-14 2013-06-12 Janssen Biotech Inc METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
EP3211094A3 (en) * 2009-09-03 2017-11-01 F. Hoffmann-La Roche AG Methods for treating, diagnosing, and monitoring rheumatoid arthritis
SG10201800757TA (en) 2010-04-20 2018-02-27 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
BR112013002831A2 (pt) 2010-08-05 2016-11-01 Anaptysbio Inc anticorpos direcionados contra a il-17
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
DK2748201T3 (en) * 2011-08-23 2018-02-12 Roche Glycart Ag BISPECIFIC T-CELL ACTIVATING ANTIGIN BINDING MOLECULES
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
SI2794658T1 (sl) 2011-12-19 2017-05-31 Synimmune Gmbh Bispecifična molekula protitelesa
CA2926859A1 (en) * 2013-10-25 2015-04-30 Board Of Regents, The University Of Texas System Polyclonal gamma delta t cells for immunotherapy
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
MA53355A (fr) 2015-05-29 2022-03-16 Agenus Inc Anticorps anti-ctla-4 et leurs procédés d'utilisation
CA3048601A1 (en) 2016-12-26 2018-07-05 Kyowa Hakko Kirin Co., Ltd. Antibody which binds to myelin oligodendrocyte glycoprotein
US11236145B2 (en) * 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
US10519236B2 (en) * 2018-01-23 2019-12-31 New York University Antibodies specific to delta 1 chain of T cell receptor
TW202144415A (zh) 2020-02-27 2021-12-01 美商健生生物科技公司 用於調節免疫反應的材料及方法
US20210284731A1 (en) 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
CN116390950A (zh) 2020-10-28 2023-07-04 詹森生物科技公司 用于调节δγ链介导的免疫的组合物和方法

Also Published As

Publication number Publication date
DOP2021000229A (es) 2022-07-31
WO2020227457A1 (en) 2020-11-12
TW202108618A (zh) 2021-03-01
PE20220763A1 (es) 2022-05-16
MA55903A (fr) 2022-03-16
JP2022533538A (ja) 2022-07-25
CA3139508A1 (en) 2020-11-12
ECSP21087921A (es) 2022-01-31
SG11202112021QA (en) 2021-11-29
CO2021015998A2 (es) 2021-12-10
EP3965818A1 (en) 2022-03-16
IL287817A (en) 2022-01-01
CN113966231A (zh) 2022-01-21
US20240150464A1 (en) 2024-05-09
CL2021002905A1 (es) 2022-06-17
AU2020267504A1 (en) 2021-12-02
KR20220017892A (ko) 2022-02-14
CR20210548A (es) 2022-02-11
US11667712B2 (en) 2023-06-06
US20210032338A1 (en) 2021-02-04
MX2021013532A (es) 2022-02-11
EP3965818A4 (en) 2023-05-31
JOP20210297A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
MX2020009326A (es) Anticuerpos anti-claudina 18.2 y usos de los mismos.
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
MX2019010922A (es) Anticuerpos anti-phf-tau y usos de estos.
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
BR112022003147A2 (pt) Novos anticorpos anti-cldn18.2
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
BR112017003194B8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição
JOP20190187A1 (ar) مترافقات عقار جسم مضاد لـ ccr7
WO2020082209A8 (zh) 抗cldn18.2抗体及其用途
WO2019217145A8 (en) Anti-dll3 antibodies and uses thereof
BR112021017801A2 (pt) Anticorpos biespecíficos anti-vbeta17/anti-cd123
BR112022003740A2 (pt) Anticorpos anti-cd96 e métodos de uso dos mesmos
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
BR112021013397A2 (pt) Anticorpos anti-tigit
BR112018072118A2 (pt) anticorpos de interferona beta e usos dos mesmos
BR112022020410A2 (pt) Anticorpos anti-phf-tau e usos dos mesmos
BR112021022089A2 (pt) Materiais e métodos para modulação da imunidade mediada por células t
EA201991845A1 (ru) Фармацевтические комбинации, содержащие антитело к ly75
WO2021173896A8 (en) Materials and methods for modulating an immune response
BR112023019546A2 (pt) Anticorpos anti-tau e usos dos mesmos
CL2021001607A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
BR112022012731A2 (pt) Anticorpo anti-ox40 e uso do mesmo
BR112022001336A2 (pt) Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo

Legal Events

Date Code Title Description
B11U Patent application definitively rejected as a later application filed via pct claims it as a priority [chapter 11.21 patent gazette]

Free format text: ARQUIVADO DEFINITIVAMENTE ESTE PEDIDO DE PATENTE, UMA VEZ QUE FOI ADMITIDO NA FASE NACIONAL BRASILEIRA O PEDIDO (112022017142-0) QUE O REIVINDICA COMO PRIORIDADE.

B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULACAO DO DESPACHO DE ARQUIVAMENTO DEFINITIVO DO PEDIDO (DESPACHO 11.21) POR TER SIDO INDEVIDO, TENDO EM VISTA A NECESSIDADE DE AVALIACAO DO CONTEUDO DOS PEDIDOS PELA AREA TECNICA.